The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
Pedro J. Romero, MD, JITC Editor-in-Chief, welcomes applications from interested individuals who would like to take advantage of the many benefits of serving as a JITC manuscript reviewer. Benefits include:
JITC launched two new sections in 2020 and is now collecting submissions for peer review. Read more about these sections, "Immune Cell Therapies and Immune Cell Engineering" and "Oncolytic and Local Immunotherapy," and submit today!
The Journal for ImmunoTherapy of Cancer (JITC) increased its impact factor to 9.913 on June 29, 2020. JITC’s Impact Factor makes JITC the highest ranked fully open access immunology journal and places it in the top 8% percent of all journals published in the categories of oncology and immunology. Published in the annual Journal Citation Reports (JCR), the latest JITC impact factor is a calculation determined on the number of 2019 citations accumulated for JITC manuscripts published in 2017 and 2018. Other valuable journal metrics for JITC may be found on the journal website.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 50 percent discount on processing fees for all JITC articles submitted and accepted in 2020.
For questions regarding the discount that would be verified and applied upon post-review acceptance, please contact JITCEditor@sitcancer.org or (414) 271-2456.
35th Anniversary Annual Meeting & Pre-Conference Programs
SITC Members: Register to Attend for Free!
Easily Become a SITC Member Through your SITC 2020 Registration
Share This Exciting Virtual Meeting Within Your Network:
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Accumulation of extracellular adenosine within the microenvironment is a strategy exploited by tumors to escape detection by the immune system. Adenosine signaling through the adenosine 2A receptor (A2AR) on immune cells elicits a range of immunosuppressive effects which promote tumor growth and limit the efficacy of immune checkpoint inhibitors. Preclinical data with A2AR inhibitors have demonstrated tumor regressions in mouse models by rescuing T cell function; however, the mechanism and role on other immune cells has not been fully elucidated.
The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in the phase 3 CheckMate 214 trial. Survival, response, and safety outcomes with NIVO+IPI versus SUN were assessed after a minimum of 42 months of follow-up.
Next week is National Postdoc Appreciation week and our friends over at the Gladstone Institutes and UCSF are hosting a post-screening panel discussion on September 25th at 2pm PT / 5pm ET. Perseverance and Creative Thinking from the Life of Jim Allison ...
Greetings SITC community, Over the summer, we've been working with a cohort of educators to develop an Educator Toolkit to accompany the film Jim Allison: Breakthrough with lesson plans, lab activities, career exploration activities, and more. ...
This comprehensive review outlines some of the immunotherapies that are currently being used to treat COVID-19 patients. Included are details of convalescent plasma therapy, monoclonal antibodies, cytokine therapy, mesenchymal stem cell therapy, intravenous ...
MedStar Health, Inc ( medstarhealth.net ) is hosting their " Melanoma and Other Skin Cancers: Biology and Patient Management 2020 " virtual conference on Saturday, November 7, 2020 . This conference will feature live speakers and Q&A, including a keynote ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org